3 August 2017 - CADTH has published its initial recommendation on the use of pembrolizumab for use by untreated patients with metastatic non-small-cell lung cancer whose tumours express PD-L1 and who do not harbour a sensitising EGFR mutation or ALK translocation.

pERC has recommended the reimbursement of pembrolizumab conditional upon its cost-effectiveness being improved to an acceptable level.

Read pERC initial recommendation for pembrolizumab